Skip to content

Developing Rectal USPE Measures for Suppositories (Project DRUM-S)

Evaluating User Perceptions and Experiences of Dual Compartment Microbicide Formulations. Project 5.3: Developing Rectal USPE Measures for Suppositories (Project DRUM-S)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02744261
Acronym
DRUM-S
Enrollment
32
Registered
2016-04-20
Start date
2016-08-11
Completion date
2022-04-01
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microbicide Delivery System Perceptibility and Acceptability

Keywords

HIV, STI, Primary Prevention, Topical Microbicides, User Experience, Drug Delivery Systems

Brief summary

The purpose of this study is to (a) adapt existing user sensory perception and experience (USPE) items/instruments generated for rectal gel/cream formulations to include USPEs specific to suppository forms for rectal and vaginal use; (b) for both male and female cohorts: to capture the experience of suppository use in the context of receptive anal intercourse (RAI); and (c) for female cohort only: to capture the experience of suppository use in the context of vaginal-penile intercourse (VI), and to compare USPEs of suppository use in the context of RAI to USPEs of suppository use in the context of vaginal-penile intercourse.

Detailed description

HIV prevention is a global public health priority. Providing efficacious prevention methods that have the greatest likelihood of use will have a profound impact on the public's health. Critical to their use is "acceptability." However, current conceptualizations of adherence and acceptability fail to fully articulate and account for patterns of use and non-use. Formulation properties are critically important to both drug delivery and the user experience. Microbicide developers thus have the opportunity to directly control a formulation's impact on acceptability and adherence to product use, as well as biological product performance. Microbicide products can and should be developed such that they achieve performance standards for both these behavioral (user experience) and biological (efficacy) functions. By incorporating the user experience early on in the product development process, developers will have the greatest chance of providing at-risk individuals with the best prevention methods science can provide. Developing prevention products that can be used in the vagina and/or the rectum and that optimize the user experience in both compartments increases the likelihood that these products will be used consistently and correctly. The impact on global public health has the potential to be far-reaching, decreasing HIV and sexually transmitted infections (STI) incidence and prevalence in both women and men. Methodology and Data Collection: This is a formative mixed methods design in which volunteers (N\ 20-30; \ 10-15 males; \ 10-15 females) will first be prescreened for basic study eligibility using a brief questionnaire. Those who are interested in the study and are eligible based on their responses to the prescreen will then complete a STI/HIV screening and pregnancy test (for females). During the course of the study, participants will evaluate 3 products: 2 distinct suppository formulations and 1 gel formulation that represent a range of rheological and other biophysical properties of potential microbicides being designed for rectal/dual compartment use. Participants will evaluate the experience of suppository use (as compared to gel use) in the context of receptive anal intercourse (RAI) among males and females, and in the context of vaginal intercourse (VI) (females). Each participant will be randomly assigned to the order in which they will evaluate the 3 products. After a sexual encounter that includes RAI/VI and study product use, participants will be required to complete a web survey about their experience with the study product.

Interventions

OTHERGel

4 mL

OTHERSuppository 1
OTHERSuppository 2

Sponsors

The Miriam Hospital
Lead SponsorOTHER
ImQuest Pharmaceuticals, Inc.
CollaboratorINDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

All participants must meet all of the inclusion criteria to participate in this study. Inclusion Criteria: All participants must meet all of the inclusion criteria to participate in this study. * Eligible male participants must be 18 years of age or older * Eligible female participants must be 18-45 years of age Inclusion criteria include men and women who: * Report receptive anal intercourse (RAI) at least twice in the past 6 months * Are willing to use each study product in conjunction with RAI on at least one occasion in each data collection period (resulting in a minimum of 3 RAI events during each product evaluation period; on average every 2 weeks, all 3 products across an average of 6 -12 weeks) * Are willing and able to respond to study data collection systems via phone and internet, attend all study visits, and participate in in-depth qualitative interviews Additional Inclusion Criteria for Female Volunteers: * Report vaginal-penile intercourse (VI) at least twice in the past 6 months * Willing to use each study suppository formulation in conjunction with VI on at least one occasion in each data collection period (resulting in a minimum of 2 vaginal intercourse events during the course of the study) * Report consistent use of an effective birth control method: e.g., hormonal contraceptive, IUD, bilateral tubal ligation, Essure® or any non-incisional permanent birth control procedure, hysterectomy (partial or total, with/without oophorectomy), partner's vasectomy/salpingectomy

Exclusion criteria

* Have a sensitivity or allergy to vaginal, anal, or rectal products * Have a sensitivity or allergy to any of the ingredients contained in the study products * Have a sensitivity or allergy to sesame seeds * Are HIV-positive at baseline, or have a known HIV-positive sexual partner * Have an active rectal or reproductive tract infection requiring treatment per current CDC guidelines or have other condition that, in the opinion of the investigator/study clinician, make the patient unsuitable for the study or unable to comply with study requirements (Note: HSV seropositivity without active genital lesions is not an

Design outcomes

Primary

MeasureTime frameDescription
User Perception Scale ScoresWeb-based survey (same survey; 3 times; one for each formulation) over an average of 6-12 weeksUSPE Sum of averaged item means/# items (min:max 1:5); 1=Do not agree at all;2=Agree a little;3=Agree somewhat;4=Agree a lot;5=Agree completely Products:Gel/Orange, Suppository 1/Green, Suppository 2/Yellow. Initial Penetration:Smoothness/lubricity; Initial Lubrication:Coating/lubricating; Spreading Behavior:Ease of stroke, product spread; Product Awareness:Feel during sex (movement, felt betw vaginal/rectal wall-penis); Perceived Wetness:Covering entire vagina/rectum; Stimulating:enhanced pleasure; Messiness:Perceptions of messiness; Leakage:Sensations of leaking during/after sex; Pre-coital Leakage:Product felt/leakage on body or clothes before sex; Naturalness:Sensation of naturalness; leakage looked like vag fluid/cum; Lubricity:Wetness before sex; slipperiness/lubricity during sex; Effortful:Effort needed at penetration; effort difficulty/dryness; Pleasure:Partner's stimulation; Noticeable:messiness, thickness. Higher scores=greater agreement re: product characteristics

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKate Guthrie, PhD

The Miriam Hospital: Centers for Behavioral & Preventive Medicine

PRINCIPAL_INVESTIGATORRobert Buckheit, PhD

ImQuest Pharmaceuticals, Inc.

Participant flow

Recruitment details

Recruited (RI, MA USA) via call-lists, flyers, ads, internet/social media, clinics, CBOs, word-of-mouth.

Pre-assignment details

One female participant was withdrawn prior to use of any study products. She was not able to follow study guidelines and did not use her first study product within the allotted time (I.e., did not use any of the three products).

Baseline characteristics

Characteristic
Age, Customized
18-29 years
15 Participants
Age, Customized
30+ years
16 Participants
History of STD Diagnosis4 Participants
Race/Ethnicity, Customized
American Indian/Alaska Native
1 Participants
Race/Ethnicity, Customized
Asian
0 Participants
Race/Ethnicity, Customized
Black
1 Participants
Race/Ethnicity, Customized
Hispanic/Latinx
6 Participants
Race/Ethnicity, Customized
More Than One Race (Black/African American, White and American Indian/Alaska Native)
1 Participants
Race/Ethnicity, Customized
More Than One Race (White and American Indian/Alaska Native)
3 Participants
Race/Ethnicity, Customized
Other Race (Not specified)
1 Participants
Race/Ethnicity, Customized
Refused
3 Participants
Race/Ethnicity, Customized
White
10 Participants
Region of Enrollment
United States
31 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
15 Participants
Vaginal Deliveries4 Participants
Yearly Income
$15,000 - $36,000
9 Participants
Yearly Income
Less than $15,000
0 Participants
Yearly Income
More than $36,000
11 Participants
Yearly Income
Refused to Answer
1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 150 / 160 / 130 / 150 / 15
other
Total, other adverse events
1 / 162 / 152 / 162 / 131 / 152 / 15
serious
Total, serious adverse events
0 / 160 / 150 / 160 / 130 / 150 / 15

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026